Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks

Diagnostic Cytopathology

Volumn 37, Issue 4, 2009, Pages 258-261

  Kim, Jo Heon ^a   Kim, Ga Eon ^a   Choi, Yoo Duk ^a   Lee, Ji Shin ^a   Lee, Jae Hyuk ^a   Nam, Jong Hee ^a   Choi, Chan ^a  

^a Chonnam National University   (South Korea)

Author keywords

Adenocarcinoma; Cell blocks; Effusion; Immunocytochemistry; Mesothelium

Indexed keywords

CALRETININ; CELL MARKER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; MONOCLONAL ANTIBODY MOC-31; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MESOTHELIUM CELL; PERITONEUM; PLEURA EFFUSION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STAINING; TUMOR CELL; TUMOR LOCALIZATION;

ADENOCARCINOMA; ASCITIC FLUID; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PLEURAL EFFUSION; SENSITIVITY AND SPECIFICITY;

EID: 65349179096     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20986     Document Type: Article

References (23)

1. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: A pattern recognition approach. Adv Anat Pathol 2006;13:174-184.
2. Koss LG, Melamed MR. Effusions in the presence of cancer. In: Koss LG, Melamed MR, editors. Koss' Diagnostic cytology and its histopathological bases. Philadelphia: Lippincott Williams & Wilkins; 2006. p 919-948.
3. Mohanty SK, Dey P. Serous effusions: Diagnosis of malignancy beyond cytomorphology-An analytic review. Postgrad Med J 2003;79:569-574.
4. Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61-66.
5. Willuda J, Honegger A, Waibel R, et al. High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59:5758-5767.
6. Morgan RL, De Young BR, McGaughy VR, Niemann TH. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999;87:390-394.
7. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-155.
8. Hecht JL, Pinkus JL, Pinkus GS. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Cancer 2006;108:56-59.
9. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy: How useful are the ''newer'' markers in body fluid cytology? Arch Pathol Lab Med 2008;132:23-28.
10. Bailey D, Baumal R, Law J, et al. Production of a monoclonal antibody specific for seminomas and dysgerminomas. Proc Natl Acad Sci USA 1986;83:5291-5295.
11. Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol 2006;34:801-806.
12. Bhalla R, Siddiqui MT, Mandich D, et al. Diagnostic utility of D2- 40 and podoplanin in effusion cell blocks. Diagn Cytopathol 2007;35:342-347.
13. Rogers JH. Calretinin: A gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol 1987;105:1343-1353.
14. Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: Utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55-60.
15. Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001;116:709-715.
16. He DN, Zhu HS, Zhang KH, et al. E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions. World J Gastroenterol 2004;10:2406-2408.
17. Lee JS, Lee MC, Park CS, Juhng SW. Diagnostic value of p53 protein and flow cytometric DNA analysis in the study of serous effusions. Acta Cytol 1997;41:1719-1725.
18. Lee JS, Nam JH, Lee MC, Park CS, Juhng SW. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions. Acta Cytol 1996;40:631-636.
19. Grefte JM, de Wilde PC, Salet-van de Pol MR, et al. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions. Acta Cytol 2008;52:35-44.
20. Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-112.
21. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME- 1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001;25:158-161.
22. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-128.
23. Delahaye M, Hoogsteden HC, Van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 1991;165:137-143.